Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
- Conditions
- Breast NeoplasmsOsteoporosis
- Interventions
- First Posted Date
- 2002-11-20
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 602
- Registration Number
- NCT00050011
- Locations
- 🇺🇸
FL Community Cancer Center, Brooksville, Florida, United States
🇺🇸Eastern Connecticut Hematology/Oncology Associates, Norwich, Connecticut, United States
🇺🇸Elmhurst Memorial Hospital, Elhurst, Illinois, United States
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Conditions
- Breast NeoplasmsNeoplasms, Hormone-dependent
- Interventions
- Drug: aromatase inhibitionProcedure: hormone therapyProcedure: endocrine therapyProcedure: antiestrogen therapy
- First Posted Date
- 2002-08-27
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 865
- Registration Number
- NCT00044291
- Locations
- 🇺🇦
Kharkov Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology Department. Clinical Facility: Kharkov Regional Clinical Oncology Dispensary, Chemotherapy Department, Kharkov, Ukraine
🇺🇦Odessa State Medical University, Oncology Department. Clinical Facility: Odessa Regional Oncology Center, Chemotherapy Department, Odessa, Ukraine
🇷🇺V. Novgorod Regional Oncology Center, Department of Chemotherapy, V. Novgorod, Russian Federation
Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
- Conditions
- McCune Albright SyndromePolyostotic Fibrous DysplasiaPrecocious Puberty
- First Posted Date
- 2000-08-14
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Target Recruit Count
- 25
- Registration Number
- NCT00006174
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 62
- Registration Number
- NCT00001521
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.